SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalAYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug


Previous 10 Next 10 
From: BioHero10/13/2017 3:23:55 PM
   of 20
 
Lots of product launches expected in the coming weeks and months which means much much higher revenue .This lextreme low float stock is definitely terrible underpriced at this price and with Nasdaq listing in sight this stock will attract more institutional investors and with such low float this stock will explode to upside .GL

------

The 10 largest shareholders alone owned almost half of the outstanding shares of 4.2 million which is very strong .

Armistice Capital LLC 405 641
Manchester Management Co. LLC 210 331
JEB Partners LP 200 000
Aigh Partners LP 181 500
Galileo Partners LLC 150 000
JMG Capital Management LLC 116 665
Joshua R. Disbrow, MBA 114 843
Jarrett T. Disbrow, PhD 113 384
Lincoln Park Capital Fund LLC 100 000

Triple Gate Capital GP LLC 100 000

Aytu BioScience Announces International Distribution Agreement for Fiera® in Japan

fintel.io

Aytu BioScience Expands MiOXSYS® Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: BioHero10/18/2017 9:50:30 AM
   of 20
 
Stock almost up 100% in last day and up today again

AYTU will start trading on Nasdaq this week
finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan1/14/2018 3:08:02 PM
   of 20
 
Jan. 12 . Up 0.40 .. +17% closed at $2.80 .. vol. 252k

stockcharts.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/8/2019 1:22:39 PM
   of 20
 
Aytu BioScience Reports 71% Revenue Growth in Q2 FY19

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/8/2019 1:23:40 PM
   of 20
 
Aytu BioScience Announces ZolpiMist (TM) Global Distribution Agreement with SUDA Pharmaceuticals

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/19/2019 1:23:35 PM
   of 20
 
Aytu BioScience Announces Two Recent Publications Highlighting Improved Efficacy and Patient Preference of Natesto Nasal Testosterone over Topical Gels

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/28/2019 4:07:53 PM
   of 20
 
Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan9/13/2019 1:43:38 AM
   of 20
 
Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan2/14/2020 2:23:08 AM
   of 20
 
Aytu BioScience's (AYTU) CEO Josh Disbrow on Q2 2020 Results - Earnings Call Transcript

seekingalpha.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/10/2020 1:36:07 PM
   of 20
 
What a move today on crazy volume ..

Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10